85 Results for "

CD80

" in MedChemExpress (MCE) Product Catalog:
Products (85)

85 Results for "CD80" in MCE Product Catalog:

6
6 Publications Verification
Cat. No.: HY-P9919
CAS No.: 1428935-60-7
Synonyms: MEDI 4736

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
loading...
    loading...
6
6 Publications Verification
Cat. No.: HY-P9919A
CAS No.: 1428935-60-7
Synonyms: MEDI 4736 (anti-PD-L1)

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99293
CAS No.: 357613-77-5
Synonyms: IDEC 114; Anti-Human CD80 Recombinant Antibody

Target:  

CD28 Apoptosis

Research Areas:  

Cancer

Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P84266
Synonyms: B7; BB1; B7-1; B7.1; LAB7; CD28LG; CD28LG1

Host:  

Mouse

Application:  

IHC-P, FC, ELISA

Reactivity:  

Human, Mouse, Rat, Rabbit

loading...
    loading...
Cat. No.: HY-108813
CAS No.: 706808-37-9
Purity:  99.30%
Synonyms: BMS 224818; LEA 29Y

Target:  

Inhibitory Antibodies

Research Areas:  

Inflammation/Immunology

Belatacept (BMS 224818) is a selective T-cell costimulation blocker and a costimulator of the CD28-CD80/86 pathway. Belatacept binds to the CD 80/86 ligand and inhibits CD-28-mediated T cell costimulation and IFN-γ production. Belatacept can be used in studies of immunosuppression in organ transplantation . The component ratio of this product is Active ingredient : Excipients = 1:2.4.
loading...
    loading...
Cat. No.: HY-P9996
CAS No.: 2445259-99-2
Synonyms: LY3434172; IBI-318

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Reozalimab (LY3434172; IBI-318) is an IgG1 monoclonal antibody targeting PD-1/PD-L1, with an IC50 of 2.27 nM and an EC50 of 0.080 nM against human PD-1, as well as an IC50 of 0.75 nM and an EC50 of 0.455 nM against human PD-L1. Reozalimab blocks the binding of PD-1 to PD-L1/PD-L2, as well as the binding of PD-L1 to PD-1/CD80, thereby inhibiting the inhibitory signal transduction of the PD-1 pathway. Reozalimab enhances the functional activation of T cells and induces anti-tumor activity in mouse tumor models reconstituted with human immune cells. Reozalimab can be used in research related to cancers such as non-small cell lung cancer and ovarian cancer .
loading...
    loading...
Cat. No.: HY-W722277A
LCC-12 (formate) is a copper (II) chelator and a derivative of the biguanide metformin (HY-B0627). LCC-12 (formate) reduces its hydrogen peroxide-dependent oxidation of NADH to NAD+. LCC-12 (formate) reduces IL-1β, IL-2, IL-6, IL-8, and TNF-α levels, as well as JAK2, STAT2, and IL-1 receptor-associated kinase 4 (IRAK4) levels in primary human cytokine-activated monocyte-derived macrophages (MDMs). LCC-12 (formate) reduces the number of CD80+ and CD86+ cytokine-activated MDMs. LCC-12 LCC-12 (formate) improves survival in a mouse model of sepsis induced by LPS or cecal ligation and puncture .
loading...
    loading...
Cat. No.: HY-P990127

Research Areas:  

Inflammation/Immunology

Anti-Mouse CD80/B7-1 Antibody (RM80) is an anti-mouse CD80/B7-1 IgG2a monoclonal antibody. Anti-Mouse CD80/B7-1 Antibody (RM80) can inhibit the number of tissue-resident memory (TRM) cells. Anti-Mouse CD80/B7-1 Antibody (RM80) can prolong the survival time of transplants combined with CD86 mAb. Anti-Mouse CD80/B7-1 Antibody (RM80) can be used for researches on inflammation conditions and immunology such as viral myocarditis and corneal transplant .
loading...
    loading...
Cat. No.: HY-P99809
CAS No.: 2254059-25-9
Synonyms: MK-1308

Target:  

CTLA-4

Research Areas:  

Cancer

Quavonlimab (MK-1308) is a humanized IgG1 monoclonal antibody targeting CTLA-4. As a competitive inhibitor of CTLA-4, Quavonlimab blocks the binding of CTLA-4 to its ligands CD80 and CD86. Quavonlimab increases interferon production, expands and activates T cells, reduces tumor regulatory T cells, inhibits tumor growth, and induces the proliferation of Ki67-positive CD4 and CD8 cells. Quavonlimab can be used in studies related to solid tumors .
loading...
    loading...
Cat. No.: HY-148511
CAS No.: 147063-80-7
Synonyms: CMP-001
Vidutolimod (CMP-001) is a virus-like particle containing a TLR9 activator . Vidutolimod induces human peripheral blood mononuclear cells to secrete IFNα, and upregulates the gene expression of CXCL10, PDL1, IDO and CD80. Vidutolimod activates TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti- antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-P99844
CAS No.: 2307144-64-3
Synonyms: ALPN-202; CD80 vIgD-Fc

Target:  

CTLA-4

Research Areas:  

Cancer

Davoceticept (ALPN-202; CD80 vIgD-Fc) is a variant CD80 vIgD-Fc fusion protein targeting CTLA-4 and PD-L1. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells .
loading...
    loading...
Cat. No.: HY-103048A
Purity:  99.34%
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases .
loading...
    loading...
Cat. No.: HY-N10116A
CAS No.: 483-77-2
Calamenene is a sesquiterpene compound . Calamenene promotes dendritic cell maturation, upregulates CD1a, CD80, CD83, CD86, HLA-DR and CCR7 on the cell surface, reduces endocytic activity, enhances T cell-stimulating capacity, drives Th1 polarization through the secretion of IL-12, induces IFN-γ production, decreases IL-4 generation, and triggers intracellular Ca 2+ mobilization as well as dendritic cell migration towards MIP-3β. Calamenene exerts bacteriostatic and bactericidal growth-inhibitory effects against pathogenic *Vibrio harveyi*. Calamenene can be used in studies related to cancer and bacterial infections .
loading...
    loading...
Cat. No.: HY-100891
CAS No.: 486449-65-4
Purity:  98.08%
Target:  

CD28

Research Areas:  

Inflammation/Immunology

CD80-IN-3, a potent CD80 inhibitor, inhibits CD80/CD28 interaction with an EC50 of 630 nM and a Kd of 125 nM.
loading...
    loading...
Cat. No.: HY-150749A
Purity:  99.82%
Target:  

IFNAR

Research Areas:  

Cancer

ODN D-SL03 sodium is a C class CpG oligonucleotides, and can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 sodium can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 sodium also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
loading...
    loading...
Cat. No.: HY-RS02269
Research Areas:  

Others

CD80 Human Pre-designed siRNA Set A contains three designed siRNAs for CD80 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS16921
Research Areas:  

Others

Cd80 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cd80 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-176265
CAS No.: 2871481-31-9
Target:  

CD28

Research Areas:  

Inflammation/Immunology

DDS5 is a CD28 inhibitor with a kd of 175.57 µM. DDS5 significantly inhibits CD28-CD80 interaction (IC50: 332 µM). DDS5 can be used for research of immune-mediated diseases, including inflammatory bowel disease and rheumatoid arthritis .
loading...
    loading...
Cat. No.: HY-P991907

Target:  

CD28

Research Areas:  

Inflammation/Immunology

Anti-CD80 Antibody (TKMF5) is an antibody against human CD80. Recommend Isotype Controls:?Human IgG1 kappa, Isotype Control (HY-P99001).
loading...
    loading...
Cat. No.: HY-103048
CAS No.: 1629654-95-0
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases .
loading...
    loading...